广济药业(000952) - 2021 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2021 was ¥785,573,171.02, representing a 14.15% increase compared to ¥688,169,323.69 in 2020[19] - The net profit attributable to shareholders for 2021 was ¥110,107,173.86, a significant increase of 47.50% from ¥74,647,103.88 in 2020[19] - The net profit after deducting non-recurring gains and losses was ¥65,639,729.59, which is a 69.85% increase from ¥38,645,048.49 in 2020[19] - The basic earnings per share for 2021 was ¥0.3201, up 43.41% from ¥0.2232 in 2020[19] - The total operating revenue for 2021 was ¥785,573,171.02, representing a year-on-year increase of 14.15% compared to ¥688,169,323.69 in 2020[50] - The net profit attributable to shareholders reached 110.11 million yuan, reflecting a significant growth of 47.50% compared to the previous year[42] - The total operating costs increased by 18.55% year-on-year, reaching 484,327,988 CNY, primarily due to the growth in pharmaceutical distribution and raw material production and sales[59] Assets and Cash Flow - The total assets at the end of 2021 were ¥2,048,896,426.54, reflecting a 3.51% increase from ¥1,979,438,635.76 at the end of 2020[20] - The net cash flow from operating activities decreased by 36.42% to ¥75,907,303.46 in 2021 from ¥119,381,525.89 in 2020[19] - The company's cash and cash equivalents decreased by ¥86,465,924.15 in 2021, a decline of 181.66% compared to an increase of ¥105,885,637.27 in 2020[71] - The proportion of accounts receivable increased to 8.93% of total assets in 2021, up from 5.26% in 2020, primarily due to new receivables from a major client[77] Research and Development - The company completed 23 patent applications in 2021, including 5 invention patents and 18 utility model patents, enhancing its R&D capabilities[42] - The R&D expenses increased by 34.28% to 52.06 million yuan, driven by investments in optimizing fermentation processes for vitamin B2 and stable production strains[43] - The number of R&D personnel rose to 203 in 2021, a 3.57% increase from 196 in 2020, with a notable increase in the number of bachelor's degree holders by 31.82%[68] - The company is actively developing multiple products in its R&D pipeline, indicating a focus on innovation and market responsiveness[99] Market and Industry Position - The company is a major global supplier of Vitamin B2, benefiting from national policies that encourage high-quality development in the raw material pharmaceutical industry[30] - The pharmaceutical industry is experiencing intensified competition due to reforms in the medical system and policies promoting centralized procurement, impacting pricing strategies[28] - The vitamin market is characterized by cyclical price fluctuations, with significant impacts from supply and demand dynamics since 2007[32] - The company aims to leverage its advantages in raw materials and technology to adapt to new economic conditions and enhance its market position[30] Corporate Governance - The company maintains a robust corporate governance structure, ensuring compliance with relevant laws and regulations, and protecting shareholder rights[103] - The board of directors consists of 9 members, including 3 independent directors, ensuring a diverse and compliant governance framework[104] - The company has established effective communication channels with investors, enhancing transparency and engagement[105] - The company has a clear ownership of assets and operates independently without any asset or fund occupation by the controlling shareholder[107] Environmental Responsibility - The company emphasizes sustainable development through green and energy-saving processes, reducing pollution and waste during production[39] - The company is classified as a key pollutant discharge unit, with specific emissions data reported for wastewater and air pollutants[159] - The average COD concentration for wastewater discharge was reported at 91.05 mg/L, with a total discharge of 48.2 tons[159] - The company has established various board committees, including the audit committee and strategic management committee, to enhance governance practices[156] Employee Management - The total number of employees at the end of the reporting period was 1,317, with 786 in production, 62 in sales, 207 in technical roles, 27 in finance, and 235 in administration[138] - The company has a training plan in place to enhance employee skills and knowledge, aiming for a win-win situation for both the company and its employees[141] - The company has a structured employee compensation scheme that includes basic salary, monthly performance, annual performance, and benefits, closely linking performance to company results[140] - The company emphasizes employee career development and has established a fair platform for professional growth[171] Strategic Initiatives - The company plans to distribute a cash dividend of ¥0.60 per 10 shares, based on a total of 343,999,939 shares[4] - The company is focusing on expanding its market presence and enhancing its product offerings through new strategies and technologies[116] - The company is actively pursuing opportunities for mergers and acquisitions to enhance its competitive position in the market[116] - The company has implemented a restricted stock incentive plan in 2021 to attract and retain key management personnel, enhancing team cohesion and competitiveness[156]